What is PrEP? (What and why?)

In the AMPrEP (Amsterdam PrEP) project, GGD Amsterdam (the local Public Health Service) is investigating the use of PrEP (Pre-Exposure Prophylaxis) for HIV prevention.

 

PrEP is a pill which contains HIV inhibitors which can prevent an HIV infection. The pill is meant for people who are not living with HIV, but who run a high risk of infection. PrEP is short for Pre-Exposure Prophylaxis. This means you take it before you are exposed to a pathogen. PrEP consists of one pill, Truvada. It contains two medications which are also used for HIV treatment: emtricitabine and tenofovir disoproxil. PrEP makes it more difficult for HIV to infect cells and to multiply. This considerably reduces the risk of an HIV infection.

prep

Aim

The project aims to investigate the use of PrEP (Pre-Exposure Prophylaxis) for HIV prevention. The research focuses on how many homosexual men and transgender people want to use PrEP, whether they adhere to the therapy, the experiences of people using PrEP overall, and whether it affects condom use. It is the first time that PrEP is being investigated in the Netherlands and our project is the first to offer participants a choice: using PrEP on a daily basis or using PrEP according to a fixed schedule around sex. GGD Amsterdam will use the project results to advise on whether to adopt PrEP as a standard intervention for HIV prevention in the Netherlands.

For more information about the Amsterdam PrEP project, visit: http://www.ggd.amsterdam.nl/english/sti-hiv-and-sense-0/prep/

waarom-w

Why?

In the past few years, the number of people newly infected with HIV has slightly decreased. Every year some 900 people are diagnosed with an HIV infection in the Netherlands, including 162 people in Amsterdam (2015).

Read more >>

aanpakken

How?

Between August 2015 and June 2016, 376 people started taking PrEP: 374 homosexual men and other men who have sex with men, and two transgender women. Of them, 273 started to use PrEP on a daily basis.

Read more >>

resultaat-w

Results

From August 2015 through May 2018, PrEP is being provided to the study participants. After this, until 1 December 2018, the participants will visit the STD polyclinic twice more. During the project’s run, interim findings will be made known, and the final results will be published at the beginning of 2019.

Read more >>

News

Team

  • Gerard Sonder
    Gerard Sonder

    Member
    GGD Amsterdam

  • Yvonne van Duijnhoven
    Yvonne van Duijnhoven

    Member
    GGD Amsterdam

  • Roel Achterbergh
    Roel Achterbergh

    Member
    GGD Amsterdam

  • Henry de Vries
    Henry de Vries

    Principal Investigator
    GGD Amsterdam/Amsterdam UMC

  • Maarten Schim van der Loeff
    Maarten Schim van der Loeff

    Member
    GGD Amsterdam

  • Udi Davidovich
    Udi Davidovich

    Member
    GGD Amsterdam

  • Elske Hoornenborg
    Elske Hoornenborg

    Project Leader
    GGD Amsterdam

  • Maria Prins
    Maria Prins

    Principal Investigator
    GGD Amsterdam/Amsterdam UMC

  • Jannie van der Helm
    Jannie van der Helm

    Member
    GGD Amsterdam

  • Arjan Hogewoning
    Arjan Hogewoning

    Member
    GGD Amsterdam/Amsterdam UMC